🇺🇸

Broad Market

· monthly

US Pre-Market SEC Filings Roundup — March 19, 2026

Across 50 overnight SEC filings, standout revenue accelerations dominate in semiconductors (Micron +196% YoY to $23.9B) and biotech (argenx +90% YoY sales to $4.15B), contrasting with declines in digital health (DarioHealth -17% YoY to $22.4M) and energy (Equinor -2.5% YoY to $43.8B), highlighting sector divergence amid mixed economic signals. Airlines (Republic +13.7% YoY revenue) and solar (SUNation +26% FY to $71.9M, beating guidance) show resilience, while SPACs (Artius II, Rice Acquisition) report trust interest offsetting losses but extended deal timelines signal delays. Capital allocation leans positive with steady dividends (Modiv $0.10/month common, Global Net Lease preferreds) and repurchases (News Corp $1B program), but debt stresses emerge (Cannabist forbearance extension, American Vanguard $225M term loan at SOFR+8.25%). Merger catalysts near (RYVYL 99% votes cast, reconvene 3/25) and routine ABS servicing compliance in 20+ filings indicate stable structured finance. Portfolio trend: 7/15 high-materiality filings show revenue growth >20% YoY averaging +80%, but 4 report cash burn or dilution; implications favor selective longs in semis/biotech pre-open.

37 high priority 13 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 18, 2026

Across 50 SEC 8-K filings from March 18, 2026, a dominant theme is extensive leadership churn with 25+ instances of C-suite appointments, resignations, and restructurings (e.g., CEOs, CFOs, COOs), signaling both proactive team-building (positive in 12 cases) and potential instability (neutral/mixed in 13). Financing activities proliferate, including $300M term loans (FTI), $2.25B term loan (Phillips 66), $40M loan facility (Hyperfine), and share repurchases ($125M ASR ExlService, $200M Accelerant), indicating strong liquidity access amid neutral-to-positive sentiment in 70% of cases. M&A/divestitures highlight strategic shifts: TriMas $1.45B aerospace sale, Independent Bank $70.2M acquisition, Energy Fuels ASM deal amendment, and RocketFuel asset sales. Period-over-period data shows outliers like Accelerant FY2025 premium +35% YoY to $4.19B and EBITDA +149% to $282M, Ovid FY2025 revenue +1122% YoY to $7.3M with op ex -20% YoY, but GAAP losses widened sharply; no broad margin compression but mixed net income trends. Capital allocation leans shareholder-friendly with buybacks and no dividend cuts reported. Portfolio implications favor monitoring industrials/energy for deal catalysts and biotechs for trial advancements, with overall positive sentiment (avg materiality 7.4/10) suggesting sector rotation opportunities into stable leadership transitions.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — March 18, 2026

Across 50 SEC filings for March 18, 2026, overarching themes include mixed financial results in 10-Ks with revenue growth in standout performers like TSS Inc (+66% YoY to $245.7M) and Bob's Discount Furniture (+16.8% YoY to $2.37B), contrasted by declines in Harte Hanks (-13.9% YoY) and persistent losses in microcaps like NRHI (net loss +6% YoY to $30.6K, zero cash). M&A activity dominates with proxy supplements for Heritage Commerce/CVB Financial (shareholder meetings March 26) and Two Harbors/UWM due to litigation risks, while capital allocation shows buybacks (TSS 988 shares, XOMA $16M, News Corp $1B program) and dividends (Heartland quarterly). Period-over-period trends reveal improving net losses in Stardust Power (-34% YoY) and XOMA (to $31.7M profit from loss), but margin compression in Bob's (-110 bps to 45.7%) and expense surges in Vyome (+790% op ex). Sector patterns highlight banking M&A hurdles, AI/tech growth (TSS backlog $115M), and pharma pipeline advances amid auditor switches (Tonix to PwC). Forward catalysts cluster in Q2 2026 (XOMA volixibat data) with IPO/ETF launches (Farlong $16M, Morgan Stanley Bitcoin). Implications favor selective longs in growth outliers amid broad small-cap weakness and litigation overhangs.

28 high priority 22 medium 50 total filings
· daily

Global High-Priority Regulatory Events — March 18, 2026

Across 50 filings in the Global High Priority Market Events stream (US SEC focus, March 18, 2026), dominant themes include heightened regulatory scrutiny with 7+ Indian-listed firms facing SEBI/BSE/NSE fines for delayed financials (totaling ~₹30L+), active M&A/takeover landscape via open offers and mergers (e.g., Nilachal Refractories, Heritage Commerce), and mixed financial performances in 10-Ks showing revenue surges in winners like TSS Inc (+66% YoY to $245.7M) offset by widening losses (e.g., dMY Squared -2145% YoY net loss). Period-over-period trends reveal strong growth outliers (avg +40% YoY revenue in consumer/industrials like Bob's Discount +16.8%, Magnum Ice Cream +4.2% organic) but margin compression (Bob's -110 bps gross) and zero-cash shells (Natural Resource Holdings). Capital allocation leans conservative with minor buybacks (TSS 988 shares) and upcoming dividends (ICICI, TVS), while forward-looking catalysts cluster around April board meetings and March 26 shareholder votes. Portfolio-level patterns flag India regulatory risks, SPAC/merger momentum, and AI/consumer growth amid ABS servicing stability. Critical implications: Monitor M&A for takeover premiums, avoid fine-hit microcaps, chase growth outliers pre-earnings.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 18, 2026

Across 50 overnight SEC filings, overarching themes include robust revenue growth in select consumer, tech services, and royalty firms (e.g., TSS +66% YoY, Bob's Discount +16.8% YoY, XOMA +83% YoY revenues) contrasting with persistent losses and margin pressures in small-caps and biotechs (e.g., NRHI net loss +2-6% YoY, Harte Hanks revenues -13.9% FY). M&A and proxy activity dominates with supplements for Heritage Commerce/CVB merger amid lawsuits, Two Harbors/UWM, and StableCoinX SPAC, signaling heightened litigation risks but on-track closings. Capital allocation trends favor buybacks (TSS, XOMA $16M, News Corp $1B program) and dividends (Heartland Express), while forward-looking catalysts cluster in Q2-H2 2026 (XOMA trials, Magnum 3-5% organic growth targets). Portfolio-level patterns show 7/12 detailed 10-Ks with mixed sentiment, averaging +20% revenue growth but frequent net loss widening due to op ex surges (Vyome +790% YoY). Sector outliers include strong consumer recovery (Bob's comp sales +7.7%) and ETF launches (Morgan Stanley Bitcoin Trust). Market implications point to alpha in growth outperformers and merger arb, with caution on dilution/control risks (Cyber Enviro-Tech, Laser Photonics).

28 high priority 22 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 17, 2026

Across 50 8-K filings from March 17, 2026, dominant themes include widespread executive and board changes (28 instances, with 18 positive appointments/promotions outweighing 10 neutral retirements/resignations), aggressive financing via convertible notes/debt (e.g., $4.3M Tenon, $500M Indivior, $124K American Rebel), and key M&A/contract wins (Fulgent $56.9M acquisition, Duos $176M GPUaaS over 36 months). Period-over-period data is sparse but highlights Bicycle Therapeutics' Q4 revenue surge +$44.3M YoY (to $48M) and FY +$37.3M (to $72.6M), offset by FY net loss widening to $219M (+$50M YoY) from R&D; no broad margin compression but dilution risks in 8 small-cap debt deals. Capital allocation shines with First Industrial's $250M open-ended buyback and Beazer Homes' 44% credit facility expansion to $525M. Sector patterns favor biotech/health (positive sentiment in 6/7 filings) and infrastructure (Duos, DTE/Google deals), signaling management conviction via experienced hires amid liquidity maneuvers. Implications: Bullish for growth-stage firms securing capital/contracts, cautious on dilution-heavy financings; portfolio tilt toward health/tech with catalysts like Duos' 75MW expansion and Clene's NIH-funded ALS program through Aug 2026.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — March 17, 2026

Across 50 SEC filings dated March 17, 2026, dominant themes include active SPAC mergers/de-SPACs (e.g., AParadise/Enhanced Games, Tri Pointe/Sumitomo, Pelican/Greenland), biotech advancements (Monte Rosa positive Phase 1 data, Cortigent IPO for brain implants), and retail/industrial turnarounds (Citi Trends +9% YoY sales, Ethos +52% revenue), contrasted by mixed financials (Mechanics Bancorp +817% net income from merger gain but rising provisions) and infrastructure stability (Brookfield +9.8% revenue). Period-over-period trends show revenue growth averaging +20% YoY in reporting firms (e.g., Citi Trends +8.9% FY sales, Dragonfly +15.8% FY), but margin pressures in 4/8 cases (Dragonfly -260bps FY gross margin, PURE mixed product lines) and net losses narrowing in biotechs/small caps (PURE -16% 6m loss). Capital allocation leans conservative (Citi Trends zero debt, Dragonfly $8.9M cost savings), with forward-looking catalysts like IPOs, FDA milestones, and merger votes driving near-term volatility. Portfolio-level patterns highlight biotech/healthcare outperformance (5/7 positive/mixed with clinical wins) vs neutral proxy/compliance noise (15+ ABS 10-Ks). M&A activity signals consolidation in homes/financials, while emerging IPOs (Cortigent $15M, BW Industrial $17M) offer growth entry points amid controlled company structures.

38 high priority 12 medium 50 total filings
· daily

Global High-Priority Regulatory Events — March 17, 2026

The 50 filings reveal a surge in SPAC/de-SPAC activity (10+ filings including Black Hawk/Vesicor, AParadise/Enhanced Games, Pelican/Greenland) with promotional interviews, extension notes, and merger progress amid positive sentiment for biotech/sports innovations. Indian insolvency events dominate critically (Jaiprakash Adani resolution with shareholder wipeout, Hindustan Zinc 55.83% promoter encumbrance, Videocon/Sumeet/Value CIRP updates), signaling distressed asset opportunities but promoter control risks. Financial trends mixed: standout revenue growth (Ethos +52% YoY to $387.6M, Mechanics Bancorp NI +817% YoY to $266M post-merger, Xerox +12.9% to $7B, McEwen +13%), but margin compressions (Xerox -4.4pts to 27.1%, Brookfield op cash -8%) and debt piles (PURE $5.52M convertibles, American Rebel 15% note). Biotech/medical advances bullish (Vesicor CEO hire, Tenon $4.3M raise, NeOnc CAO), IPOs/S-1s active (Cortigent brain implants $4-6B TAM, BW Industrial $17M), capital allocation favors buybacks (First Industrial $250M). Portfolio patterns: SPAC catalysts near-term, Indian miners bearish leverage, US small caps growth via M&A/debt; implications for alpha in de-SPACs, caution on distress.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 17, 2026

Overnight SEC filings from March 16-17, 2026 reveal mixed financial performance across sectors, with standout YoY revenue growth in select names like Mechanics Bancorp (+817% net income post-merger), Ethos Technologies (+52% revenue), and PURE Bioscience (+21.7% six-month revenue), contrasted by margin compressions in Dragonfly Energy (-250 bps gross margin QoQ) and Xerox Holdings (-440 bps total gross margin). SPAC and M&A activity dominates with positive sentiment around AParadise/Enhanced Games merger ($1.3B valuation), Pelican/Greenland energy deSPAC, and Two Harbors/UWM acquisition push, while activist pressure mounts at Lululemon via Dennis Wilson's 8.4% stake and board criticism. Capital allocation trends favor buybacks (First Industrial $250M program) and debt settlements (Integrated Rail), but dilutive financings (American Rebel 15% effective note, Hammer related-party loans) raise dilution risks. Forward-looking catalysts include BioCardia FDA pre-submission acceptance, Dragonfly Q1 2026 guidance ($9.5M sales, -$4.6M Adj EBITDA), and multiple proxy meetings (Carlisle April 29). Routine ABS servicing compliance in 10+ 10-Ks signals stable RMBS/ABS operations with no material issues. Portfolio-level, 7/15 high-materiality filers show revenue growth averaging +25% YoY but mixed profitability, favoring opportunistic plays in SPACs and post-merger banks amid pre-market positioning.

39 high priority 11 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 16, 2026

Across 50 SEC filings from March 16, 2026, dominant themes include a surge in M&A activity (8 deals closed, amended, or announced, e.g., Quipt going private at $3.65/share, Interactive Strength acquiring Ergatta for $8.75M+ equity), widespread executive transitions (20+ resignations, appointments, retirements across CEOs, CFOs, directors), and debt refinancings/capital raises (12 issuances totaling >$25B, often extending maturities or funding growth). Period-over-period trends where reported show mixed results: Urgent.ly Q4 revenue +4% YoY (gross margin +400bps to 26%) but FY revenue -10% YoY; Dragonfly FY revenue +15.8% YoY (OEM +33.8%) but Q4 gross margin -260bps to 18.2% and net loss widened to $(69.9M). Capital allocation leans toward buybacks (Boston Beer $25M plan), executive equity grants (Victory $79.4M, Deere $35M), and deleveraging (Armada Hoffler $562M asset sale). Biotech/pharma outliers shine with positive financings (Alto $120M, Acumen $35.75M); real estate/financials focus on restructuring. Market implications: heightened M&A signals consolidation in small-caps, leadership churn may introduce volatility but signals continuity via interim appointments, debt activity supports liquidity amid higher rates.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — March 16, 2026

Across 50 SEC filings for March 16, 2026, mixed FY2025 financials dominate with 12/20 10-Ks showing revenue declines averaging -10% YoY (e.g., Townsquare -5.2%, iQIYI -6.6%, LivePerson -22%) offset by outliers like Figure Technology +48.7% and WaterBridge +66%, while margins improved in 7/15 cases via cost cuts (e.g., Townsquare op income +103.8%). M&A and restructuring activity surges in real estate (Kennedy-Wilson amendment, Armada Hoffler $562M sale) and biotech/pharma (Alto Neuroscience pipeline, Urgent.ly merger), alongside capital returns like Amphastar $50M buyback increase and Townsquare $0.20 dividend maintenance. Management transitions signal continuity (CoStar AI expert director, KORU CEO succession), but risks loom from widening losses (Alto -3% YoY net loss) and leverage rises (WaterBridge borrowings +140% YoY). Sector pivots to AI/HPC (Mawson, CoStar) and positive guidance (Townsquare FY2026 $420-440M revenue) point to recovery potential, with portfolio-level trends favoring cost discipline amid soft revenue. Implications: Favor resilient growth names like PCB Bancorp (+45% net income) and Blend Labs (loss narrowing to $7M), monitor merger votes for catalysts.

31 high priority 19 medium 50 total filings
· daily

Global High-Priority Regulatory Events — March 16, 2026

Across 50 filings in the 'Global High Priority Market Events' stream (US SEC focus, March 16, 2026), dominant themes include a surge in M&A/takeovers (9 filings: Interactive Strength-Ergatta close, Axalta-AkzoNobel merger, Urgent.ly-Agero acquisition), SPAC/de-SPAC extensions/promotions (Xanadu, FACT II, Trailblazer), and financial distress in Indian firms (MTNL defaults ₹2,096 Cr overdue, Quadrant CIRP extension to May 30, 2026). Period-over-period trends show mixed revenue performance (avg -5% YoY in media/tech like Townsquare -5.2%, iQIYI -6.6%; +30-50% in select fintech/energy like Figure Tech +48.7%, WaterBridge +66%), with net losses narrowing in 6/15 reporting cos (e.g., Blend Labs -84% YoY to $7M, Urgent.ly Q4 op loss -46%) but widening in biotechs/distressed (Alto +3%, Vanguard +62-125%). Capital allocation leans defensive (Airbnb $2.5B debt refinance to 2029-2036 despite +4.4-5.25% rates; PCB dividends +11% to $0.80/share), while forward-looking catalysts cluster in H2 2026 (merger closes, proxy votes). Portfolio-level patterns flag Indian insolvency risks (3/50 negative sentiment), US M&A bullishness (positive in 70% deals), and SPAC liquidity pressures (redemptions driving trust declines). Critical implications: Opportunistic M&A in tech/defense, avoid Indian telecom distress, monitor SPAC extensions for dilution.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 16, 2026

Overnight SEC filings reveal mixed financial performances across sectors, with standout growth in infrastructure (WaterBridge +66% YoY revenue), fintech (Figure Technology +48.7% revenue, +574% net income), and banking (PCB Bancorp +45% net income), contrasted by declines in media (Townsquare -5.2% revenue, iQIYI -6.6%), biotech (Alto Neuroscience -3% net loss widening), and digital services (LivePerson -22% revenue). M&A activity surges with Kennedy-Wilson merger amendments requiring 2/3 vote excluding insiders, Urgent.ly acquisition by Agero, and Armada Hoffler $562M asset sale; capital returns strengthen via Amphastar $50M buyback expansion, Townsquare $0.20 dividend maintenance (11% yield), and WaterBridge $0.05 quarterly dividend initiation. Forward guidance mixed: Townsquare FY26 revenue $420-440M (-2% implied), WaterBridge EBITDA $420-460M (+7-9%); pipeline catalysts abound in biotech (Alto ALTO-101 data 1Q26). Portfolio trends show 8/15 profitable firms improving margins via cost cuts (avg op ex -20%), but 6/10 report rising debt/interest (e.g., Townsquare +32%). Real estate simplification and SPAC extensions signal defensive positioning amid volatility, with AI/quantum themes bullish (CoStar, Xanadu). Implications: Favor infra/fintech longs, monitor media turnarounds and biotech catalysts for alpha.

31 high priority 19 medium 50 total filings
· daily

Global High-Priority Regulatory Events — March 15, 2026

Across these two high-priority market event filings, themes center on operational stability amid rumors in the metals sector and upcoming earnings catalysts in IT services, both from major Indian firms with US exposure via ADRs. Hindalco's positive rumor verification highlights minimal disruption (<0.1% impact) from gas supplier force majeure, underscoring resilience in commodities amid geopolitical noise like Iran war reports. Infosys announces a high-materiality (9/10) board meeting for Q4/FY2026 results and potential dividend, signaling routine but critical capital allocation decisions under SEBI compliance. No direct period-over-period financial trends are reported in these event-driven filings, but forward-looking catalysts dominate, with Infosys' trading window closure (March 16-April 27, 2026) implying material non-public info. Portfolio-level patterns show low-risk clarification for Hindalco (materiality 3/10) versus high-impact earnings for Infosys, suggesting relative outperformance potential in IT over metals short-term. Market implications include reduced uncertainty for Hindalco and pre-earnings positioning for Infosys, with both reinforcing SEBI regulatory transparency.

2 high priority 2 total filings
· daily

Global High-Priority Regulatory Events — March 14, 2026

The 17 filings reveal a surge in high-priority distress events among Indian listed companies, dominated by insolvency proceedings (10/17), with 70% showing positive progress via settlements, unanimous approvals, and scheme sanctions, signaling potential turnarounds amid CIRP protections. Negative outliers include Reliance Communications' subsidiary fraud classification on ₹375 Cr pre-CIRP loans (₹125 Cr SBI), Tijaria Polypipes' new Bank of India insolvency petition, and Olympic Cards' ₹0.15 Cr loan default on ₹15.5 Cr facility. No aggregate period-over-period financial trends available, but specific metrics highlight distress like Olympic's ₹9.28 Cr bank borrowings and 100% creditor approvals in restructurings (e.g., Share India 99.8% equity votes). Open offers (Lykis, Satani Bearings) and minor regulatory actions (Manappuram ₹2.7L penalty) add neutral-to-positive M&A/takeover themes. Three medium-risk encumbrances (Anand Rathi Wealth, India Finsec, unknown) warrant monitoring. Portfolio implications: Bullish resolution momentum for alpha in distressed assets, bearish fraud/default risks for avoidance; key catalysts cluster March-April 2026.

17 high priority 17 total filings
· daily

US Material Events SEC 8-K Filings — March 13, 2026

The 50 8-K filings from March 13, 2026, reveal a surge in financing activities (12+ cases), including credit expansions, note issuances, and debt-for-equity swaps, signaling robust liquidity amid stable economic conditions; energy firms dominate positive developments with accretive acquisitions and $20.7B+ project financings. Executive transitions affect 15+ companies (resignations/appointments), mostly neutral/mixed but clustered in tech/healthcare, potentially signaling churn without major disagreements. Capital allocation trends favor shareholders via $10M repurchases (HealthStream), buyback permissions ($50M AMC), and hedging (Vitesse 67% 2026 oil hedged at $64-67/Bbl), contrasting dilutive raises (Olenox Series C, Functional Brands exchanges). M&A/asset sales (7 cases) show mixed pro forma impacts, e.g., Kaanapali $10.3M gain but sales declines YoY. No widespread margin compression; instead, operational enhancements (Battalion 30 drilling locations added) and forward contracts (ETHZilla 12-13% yields). Highest materiality events (10/10: IF Bancorp merger delist, Venture Global FID) imply sector rotation to energy/LNG; watch fintech tokenization and REIT dispositions for alpha.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — March 13, 2026

Across 50 SEC filings for March 13, 2026, key themes include mixed FY2025 results with revenue growth averaging +15% YoY in reporting companies (e.g., ONE Group +19.7%, Emerald +16.2%, Tonix +30% product rev) offset by Q4 weakness and margin pressures in hospitality/REITs, alongside robust capital allocation via dividends (GIII $0.10/share, Emerald $0.015/share, First Northern 5% stock dividend) and buybacks (Emerald $17.5M repurchased, $25M remaining; News Corp $1B program). Energy sector shines with Venture Global's $20.7B CP2 LNG financing (no equity dilution) positioning it as top US exporter at 100+ MTPA, and Battalion Oil's accretive acquisition adding 30 drilling locations. Pharma/biotech shows launches (Tonix TONMYA) but high cash burn; banks/REITs mixed with NIM expansion (First Northern +17 bps to 3.77%) but deposit declines. Forward guidance optimistic in hospitality/events (ONE Group $840-855M rev 2026, Emerald $490-495M), while insider activity neutral (Walmart 10b5-1 plans for diversification). Portfolio-level: 6/10 detailed filers issued upbeat 2026 guidance, but 4/10 reported net losses widening YoY; M&A/acquisitions in 5 filings signal consolidation. Implications: Favor energy/infrastructure over cyclical hospitality amid quiet deposit growth in banks.

32 high priority 18 medium 50 total filings
· daily

Global High-Priority Regulatory Events — March 13, 2026

Across 50 filings in the Global High Priority Market Events stream (US SEC focus with global insolvency/takeover/regulatory themes), key themes include robust energy project financings and acquisitions contrasting with Indian insolvencies and mixed bank/REIT 10-K results; period-over-period trends show 7/15 10-Ks with revenue growth averaging +20% YoY (e.g., Perfect Corp +14.9%, SenesTech +20%) but 4 with declines averaging -11% (Quest -13.2%), NIM expansions in 3 banks (+14-37 bps), and portfolio expansions in BDCs/lenders. Critical developments feature Venture Global's $8.6B CP2 LNG FID (total $20.7B financing, +100 MTPA capacity), BlackRock's stake increase in Sammaan Capital (+0.06%), and multiple Indian insolvencies (Punj Lloyd, Shree Hanuman). Capital allocation highlights buybacks (CCEP €1B completed, First Northern repurchase program), dividends (5% stock dividend), and financings; insider patterns show institutional buying but key resignations (Greenpanel President, Nine Energy GC). Market implications point to energy export strength amid LNG demand, bank resilience despite deposit shifts, and distress opportunities in India, with catalysts like CoC meetings and IPOs driving near-term volatility.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 13, 2026

Overnight SEC filings for March 13, 2026, reveal a mix of FY2025 10-K annual reports dominating (e.g., banks, pharma, REITs, BDCs), with period-over-period trends showing resilient revenue growth in select pharma/biotech (avg +25% YoY for Tonix, SenesTech, Vaxart) and banks (Red River net income +25% YoY, First Northern NII +4.8%), but widespread margin pressures and operating losses in industrials/REITs (Quest revenue -13% YoY, BRT NOI flat). Capital allocation leans positive with buybacks (News Corp $1B program, First Northern 1M+ shares authorized), dividends (BRT AFFO +3%), and financings (Karman +$100M revolver, Olenox $810k preferred). Auditor changes (Amplify material weakness) and litigation (Scilex fraud suit) flag risks, while M&A/acquisitions (Battalion 7k acres all-stock) and guidance (Emerald FY26 revenue $490-495M) offer catalysts. Sector themes include banking NIM expansion (Red River +14 bps to 3.38%) vs deposit declines, BDC portfolio ramps (Unknown Co net assets +huge from inception), and mixed pharma commercialization ramps amid high cash burn. Portfolio-level: 12/20 10-Ks mixed sentiment, cash positions strengthened in 8/15 reporting cos (e.g., Tonix to $207M), signaling near-term runway but watch for Q1 2026 guidance shifts. Actionable: Favor banks/BDCs with NIM/ROE gains, avoid litigation-exposed biotech.

35 high priority 15 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 12, 2026

Across 50 US SEC 8-K filings dated March 12, 2026, dominant themes include widespread board expansions and executive appointments (20+ instances, e.g., healthcare/tech sectors), signaling proactive governance refreshes amid growth ambitions. Capital raising activity is robust with 15+ financings/debt deals totaling >$3B (e.g., CACI $500M notes, NGL $950M term loan, Longeveron $30M PP), extending runways and refinancing maturities, though some mixed with dilution/waivers. M&A completions/ announcements (8 filings, e.g., Laird $38.5M Navitas, T Stamp dual acqs) highlight consolidation in consumer health/tech, while operational distress appears isolated (Vestand closures/resignations). No aggregate YoY/QoQ financial trends due to 8-K focus on events, but capital allocation leans toward debt optimization (10+ refinancings) over dividends/buybacks. Bullish sentiment prevails (60% positive/neutral), with healthcare (Longeveron trial data 3Q26) and fintech leading; bearish outliers in retail/food (Vestand). Implications: Favor liquidity-strong firms pre-earnings; monitor SPACs/mergers for catalysts. Portfolio pattern: Activist settlements (Turtle Beach) and CEO transitions (Build-A-Bear) indicate stabilizing managements.

50 high priority 50 total filings